Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yin Dai

Showing results (11-20 of 189) with videos related to

Pageof 19
Sort By:
American Journal of Nephrology|September 20, 2008
Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in ratsMing Xu, De-Zai Dai, Yin Dai
Technology and Health Care : Official Journal of the European Society for Engineering and Medicine|May 11, 2016
Research on medical image encryption in telemedicine systemsYin Dai, Huanzhen Wang, Zixia Zhou, et al.
European Journal of Pharmacology|October 19, 2013
AQP4 KO exacerbating renal dysfunction is mediated by endoplasmic reticulum stress and p66Shc and is attenuated by apocynin and endothelin antagonist CPU0213Yu-Si Cheng, De-Zai Dai, Yin Dai
Reproductive Toxicology (Elmsford, N.Y.)|March 24, 2010
Testis dysfunction by isoproterenol is mediated by upregulating endothelin receptor A, leptin and protein kinase Cvarepsilon and is attenuated by an endothelin receptor antagonist CPU0213Yu-Si Cheng, De-Zai Dai, Yin Dai
The Journal of Pharmacy and Pharmacology|May 2, 2009
Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycinYu-Si Cheng, De-Zai Dai, Yin Dai
Acta Pharmacologica Sinica|July 15, 2009
Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213Yu-si Cheng, De-zai Dai, Yin Dai
The Journal of Pharmacy and Pharmacology|July 9, 2010
NaHS ameliorates diabetic vascular injury by correcting depressed connexin 43 and 40 in the vasculature in streptozotocin-injected ratsYu-Fen Zheng, De-Zai Dai, Yin Dai
Life Sciences|July 11, 2006
Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in ratsHui-Jing Xia, De-Zai Dai, Yin Dai
Acta Pharmacologica Sinica|August 23, 2006
CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-kappaB in ratsHai-bo He, De-zai Dai, Yin Dai
Frontiers in Public Health|March 14, 2022
Green Logistics and Health in OBRI Economies: Does Social Marketing Matter?Lingyun Zhang, Hsu Ling Chang, Yin Dai, et al.
Pageof 19

Showing results (11-20 of 189) with videos related to

Sort By:
Pageof 19
American Journal of Nephrology|September 20, 2008
Normalizing NADPH oxidase contributes to attenuating diabetic nephropathy by the dual endothelin receptor antagonist CPU0213 in ratsMing Xu, De-Zai Dai, Yin Dai
Technology and Health Care : Official Journal of the European Society for Engineering and Medicine|May 11, 2016
Research on medical image encryption in telemedicine systemsYin Dai, Huanzhen Wang, Zixia Zhou, et al.
European Journal of Pharmacology|October 19, 2013
AQP4 KO exacerbating renal dysfunction is mediated by endoplasmic reticulum stress and p66Shc and is attenuated by apocynin and endothelin antagonist CPU0213Yu-Si Cheng, De-Zai Dai, Yin Dai
Reproductive Toxicology (Elmsford, N.Y.)|March 24, 2010
Testis dysfunction by isoproterenol is mediated by upregulating endothelin receptor A, leptin and protein kinase Cvarepsilon and is attenuated by an endothelin receptor antagonist CPU0213Yu-Si Cheng, De-Zai Dai, Yin Dai
The Journal of Pharmacy and Pharmacology|May 2, 2009
Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycinYu-Si Cheng, De-Zai Dai, Yin Dai
Acta Pharmacologica Sinica|July 15, 2009
Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213Yu-si Cheng, De-zai Dai, Yin Dai
The Journal of Pharmacy and Pharmacology|July 9, 2010
NaHS ameliorates diabetic vascular injury by correcting depressed connexin 43 and 40 in the vasculature in streptozotocin-injected ratsYu-Fen Zheng, De-Zai Dai, Yin Dai
Life Sciences|July 11, 2006
Up-regulated inflammatory factors endothelin, NFkappaB, TNFalpha and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in ratsHui-Jing Xia, De-Zai Dai, Yin Dai
Acta Pharmacologica Sinica|August 23, 2006
CPU0213, a novel endothelin receptor antagonist, ameliorates septic renal lesion by suppressing ET system and NF-kappaB in ratsHai-bo He, De-zai Dai, Yin Dai
Frontiers in Public Health|March 14, 2022
Green Logistics and Health in OBRI Economies: Does Social Marketing Matter?Lingyun Zhang, Hsu Ling Chang, Yin Dai, et al.
Pageof 19